Stockscreener 앱 받기
1.84
3.16%
-0.06
시간 외 거래:
1.89
0.05
+2.72%
전일 마감가:
$1.90
열려 있는:
$1.85
하루 거래량:
645.66K
Relative Volume:
0.67
시가총액:
$58.65M
수익:
-
순이익/손실:
$-38.06M
주가수익비율:
-0.7816
EPS:
-2.3541
순현금흐름:
$-11.86M
1주 성능:
+2.22%
1개월 성능:
+0.00%
6개월 성능:
-38.05%
1년 성능:
-15.60%
1일 변동 폭
$1.80
$1.88
1주일 범위
$1.80
$2.23
52주 변동 폭
$1.58
$3.84
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
명칭
Nrx Pharmaceuticals Inc
전화
484-254-6134
주소
1201 ORANGE STREET, WILMINGTON
Compare NRXP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
1.84 | 60.56M | 0 | -38.06M | -11.86M | -2.3541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-08 | 개시 | H.C. Wainwright | Buy |
| 2025-04-02 | 개시 | BTIG Research | Buy |
Nrx Pharmaceuticals Inc 주식(NRXP)의 최신 뉴스
NRx Pharmaceuticals, Inc. to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 - Investing News Network
NRx Pharmaceuticals (NASDAQ: NRXP) Schedules March 24 Conference Call To Review 2025 Results, Clinical Progress - Digital Journal
Nrx Pharmaceuticals, Inc. (Nasdaq NRXP) to report full year 2025 financial results and provide a corporate update on March 24, 2026 - marketscreener.com
NRx Pharmaceuticals to Host Conference Call on March 24, 2026, to Discuss Financial Results and Drug Development Progress - Quiver Quantitative
NRx Pharmaceuticals, Inc. (NRXPW) Stock Price, News, Quote & History - Yahoo Finance
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026 - GlobeNewswire Inc.
D Boral Capital maintains NRx Pharmaceuticals (NRXP) buy recommendation - MSN
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS), Airsculpt Technologies (AIRS) and NRX Pharmaceuticals (NRXP) - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Stoke Therapeutics (STOK), NRX Pharmaceuticals (NRXP) and Airsculpt Technologies (AIRS) - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
NRx Pharmaceuticals receives FDA bioequivalence approval notice By Investing.com - Investing.com India
Joseph Michael Casper Net Worth (2026) - GuruFocus
NRx Pharmaceuticals Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application - citybiz
NRx Pharmaceuticals receives FDA bioequivalence approval notice - Investing.com
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRx’s Preservative-Free Ketamine Application - The Manila Times
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA - GlobeNewswire
NRx Pharmaceuticals receives FDA guidance on NRX-100 drug application By Investing.com - Investing.com South Africa
HC Wainwright & Co. Reiterates NRx Pharmaceuticals (NRXP) Buy Recommendation - MSN
Dip Buying: Is NRx Pharmaceuticals Inc Equity Warrant forming a breakout pattern - baoquankhu1.vn
NRx Pharma stock jumps after FDA signals path to NDA for ketamine depression drug - MSN
NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100 - Digital Journal
NRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Why Is NRx Pharma Stock Gaining Monday?NRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga
Will KETAFREE Become The First FDA-Approved Preservative-Free Ketamine Formulation? - RTTNews
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting - Bitget
NRx Pharmaceuticals Confirms Path to New Drug Application - citybiz
NRX Pharmaceuticals confirms path to new drug application with real world data and broader proposed indication for NRX-100 (Ketamine) following type C FDA meeting - marketscreener.com
NRx Pharmaceuticals receives FDA guidance on NRX-100 drug application - Investing.com
FDA lets ketamine depression drug seek approval without new trials - Stock Titan
NRx Pharma Stock Jumps After FDA Signals Path To NDA For Ketamine Depression Drug - Sahm
NRx Pharmaceuticals appoints Joshua C Brown chief medical innovation officer - MSN
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints TMS, Neuroplasticity Researcher Joshua Brown MD, PhD, as Chief Medical Innovation Officer - Digital Journal
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - The Malaysian Reserve
Big Money Moves: Is NRx Pharmaceuticals Inc backed by strong institutional buying2026 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
NRx Pharmaceuticals Appoints Joshua C. Brown Chief Medical Innovation Officer - MyChesCo
D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP) - MarketBeat
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment - Digital Journal
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD - The Manila Times
NRx Pharmaceuticals (NRXP) to Release Earnings on Friday - MarketBeat
HC Wainwright Has Positive Estimate for NRXP FY2026 Earnings - MarketBeat
What are NRx Pharmaceuticals Inc. Equity Warrant’s growth leversQuarterly Portfolio Summary & Low Risk Entry Point Guides - mfd.ru
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 By Investing.com - Investing.com India
H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 - Investing.com Nigeria
Q3 EPS Forecast for NRx Pharmaceuticals Decreased by Analyst - MarketBeat
NRXP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NRx Pharmaceuticals (NASDAQ:NRXP) Stock Rating Upgraded by Zacks Research - MarketBeat
NRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $45.00 - MarketBeat
NRx Pharmaceuticals appoints Joshua Brown as chief medical officer - Investing.com
NRx Pharmaceuticals (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer - Digital Journal
NRx Pharmaceuticals (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway - Digital Journal
Nrx Pharmaceuticals Inc (NRXP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):